Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use
Kayla Barekat, Soumita Ghosh, Christin Herrmann, Karl Keat, Charles-Antoine Assenmacher, Ceylan Tanes, Naomi Wilson, Ronan Lordan, Antonijo Mrčela, Lubica Rauova, Arjun Sengupta, Ujjalkumar Subhash Das, Robin Joshi, Elliot Friedman, Marylyn D. Ritchie, Kyle Bittinger, Aalim Weljie, Ken Cadwell, Frederic D. Bushman, Gary D. Wu, Garret A. FitzGerald, Emanuela Ricciotti
Kayla Barekat, Soumita Ghosh, Christin Herrmann, Karl Keat, Charles-Antoine Assenmacher, Ceylan Tanes, Naomi Wilson, Ronan Lordan, Antonijo Mrčela, Lubica Rauova, Arjun Sengupta, Ujjalkumar Subhash Das, Robin Joshi, Elliot Friedman, Marylyn D. Ritchie, Kyle Bittinger, Aalim Weljie, Ken Cadwell, Frederic D. Bushman, Gary D. Wu, Garret A. FitzGerald, Emanuela Ricciotti
View: Text | PDF
Research Article Gastroenterology Inflammation

Concomitant COX-1 and COX-2 suppression is not sufficient to induce enteropathy associated with chronic NSAID use

  • Text
  • PDF
Abstract

NSAIDs are the most widely used medications for the management of chronic pain; however, they are associated with numerous gastrointestinal (GI) adverse events. Although many mechanisms have been suggested, NSAID-induced enteropathy is thought to be primarily due to inhibition of both COX-1 and -2, which results in suppression of prostaglandin synthesis. Yet surprisingly, we found that concomitant postnatal deletion of Cox-1 and -2 over 10 months failed to cause intestinal injury in mice unless they were treated with naproxen or its structural analog, phenylpropionic acid, which is not a COX inhibitor. Cox double-knockout mice exhibited a distinct gut microbiome composition, and cohousing them with controls rescued their dysbiosis and delayed the onset of NSAID-induced GI bleeding. In both the UK Biobank and All of Us human cohorts, coadministration of antibiotics with NSAIDs was associated with an increased frequency of GI bleeding. These results showed that prostaglandin suppression played a trivial role in NSAID-induced enteropathy. However, Cox deletion caused dysbiosis of the gut microbiome, which amplified the enteropathic response to NSAIDs.

Authors

Kayla Barekat, Soumita Ghosh, Christin Herrmann, Karl Keat, Charles-Antoine Assenmacher, Ceylan Tanes, Naomi Wilson, Ronan Lordan, Antonijo Mrčela, Lubica Rauova, Arjun Sengupta, Ujjalkumar Subhash Das, Robin Joshi, Elliot Friedman, Marylyn D. Ritchie, Kyle Bittinger, Aalim Weljie, Ken Cadwell, Frederic D. Bushman, Gary D. Wu, Garret A. FitzGerald, Emanuela Ricciotti

×

Figure 1

Postnatal deletion of Cox-1 and -2 reveals that chronic PG depletion alone is not sufficient to induce spontaneous GI injury in mice.

Options: View larger image (or click on image) Download as PowerPoint
Postnatal deletion of Cox-1 and -2 reveals that chronic PG depletion alo...
(A) Longitudinal tracking of universal inducible Cox-DKO mice was conducted over 10 months after tamoxifen exposure (administered at 10–12 weeks of age). Monthly urinary PGI2 (PGIM), PGD2 (PGDM), PGE2 (PGDM), and thromboxane (TxM) metabolite levels measured by LC-MS/MS, analyzed separately for each sex. n = 14 Cox-DKO mice and 6 Cre–/– controls. (B) Attempted induction of PG synthesis in Cox-DKO mice via LPS challenge. Mice received 1 mg/kg BW LPS by i.p. injection, and urine was collected overnight. n = 7–9 mice per group. Urinary PG metabolites measured by LC-MS/MS for male and female Cox-DKO mice and Cre–/– controls at baseline versus post-LPS exposure. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA. (C) Total ulcer count throughout the entire GI tract (including stomach, small intestine, and large intestine), as counted by a blinded pathologist, paired with qualitative/semiquantitative pathology scores throughout the entire GI tract for longitudinal tracking experiment. Each data point represents a single mouse. (D) Weekly hemoccult test results plotted as a Kaplan-Meier curve for percentage of each group that tested negative for blood in the stool. Any individual that tested positive was marked positive for that first week and all subsequent weeks, resembling a survival curve.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts